GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EGEIRO Pharma (XPAR:ALVET) » Definitions » Float Percentage Of Total Shares Outstanding

EGEIRO Pharma (XPAR:ALVET) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 07, 2025)


View and export this data going back to 2021. Start your Free Trial

What is EGEIRO Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, EGEIRO Pharma's float shares is 0.00 Mil. EGEIRO Pharma's total shares outstanding is 122.21 Mil. EGEIRO Pharma's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, EGEIRO Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, EGEIRO Pharma's Institutional Ownership is 1.16%.


EGEIRO Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

EGEIRO Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/122.21
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EGEIRO Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EGEIRO Pharma (XPAR:ALVET) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
N/A
Address
Avenue Jean Mermoz 32/1, Gosselies, BEL, 6041
EGEIRO Pharma is a biopharmaceutical company. The company is focused on the clinical development of drugs for Idiopathic Pulmonary Fibrosis, a chronic, devastating, and fatal disease characterized by the deterioration of lung function.

EGEIRO Pharma Headlines

No Headlines